Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

This study has been completed.

Study NCT00075634 Information provided by National Cancer Institute (NCI)

First Received: January 9, 2004 Last Updated: December 28, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	September 2007 (Final data collection date for primary outcome measure)

Publications:

George RE, Lahti JM, Adamson PC, Zhu K, Finkelstein D, Ingle AM, Reid JM, Krailo M, Neuberg D, Blaney SM, Diller L. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study. Pediatr Blood Cancer. 2010 Jun 29; [Epub ahead of print]

George R, Lahti J, Ingle M, et al.: Decitabine (DAC) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in relapsed neuroblastoma (NBL): a Children's Oncology Group study. [Abstract] J Clin Oncol 25 (Suppl 18): A-9565, 542s, 2007.

George RE, Medeiros-Nancarrow C, Adamson PC, et al.: A phase I study of decitabine (DCT) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in the treatment of relapsed or refractory solid tumors - a Children's Oncology Group study. [Abstract] J Clin Oncol 23 (Suppl 16): A-8530, 807s, 2005.